This trial will test whether the drug guselkumab is effective and safe for people with Crohn's disease.
2 Primary · 4 Secondary · Reporting Duration: Up to 109 Weeks
Experimental Treatment
Non-Treatment Group
318 Total Participants · 3 Treatment Groups
Primary Treatment: Guselkumab Dose 3 · Has Placebo Group · Phase 3
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:North Carolina | 50.0% |
Texas | 50.0% |
18 - 65 | 100.0% |
Did not meet criteria | 50.0% |
Met criteria | 50.0% |
3+ | 100.0% |